Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 25, 2025JNCI Journal of the National Cancer Institute

Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

RARiona AburakiYFYu FujiwaraSHSaya Haketa

Discussion

Loading...

Member takes

Overview

Systematic review evaluates neoadjuvant therapy impacts on survival outcomes in patients with NSCLC, suggesting optimal strategies remain unclear.

Key Points

  • Immune checkpoint inhibitors have improved outcomes in patients with resectable non-small cell lung cancer.
  • Comparisons of seven perioperative strategies showed no clear benefit from adding adjuvant ICI therapy to neoadjuvant chemoimmunotherapy.
  • The analysis included 11 randomized controlled trials with 4,532 patients, using a random model network meta-analysis.
  • Further research is essential to establish the best treatment strategies for resectable non-small cell lung cancer.

Cite This Study

Aburaki et al. (2025) studied this question.

synapsesocial.com/papers/689a0933e6551bb0af8ce4c3https://doi.org/10.1093/jnci/djaf190
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Real‐World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?2025 · 3 citations
  2. 2Comparison of the efficacy of immunotherapy at different time points during the perioperative period for stage II-III NSCLC.2024
  3. 3The Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer2026
  4. 4Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non–Small Cell Lung Cancer2026
  5. 5Moving Immunotherapy Into the Treatment of Resectable Non–Small Cell Lung Cancer2024 · 17 citations